Press release content from Business Wire. The AP news staff was not involved in its creation.
Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion
February 10, 2021 GMT
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Feb 10, 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease on schedule to be announced in Q4 2021 and a pipeline of therapeutics for degenerative diseases, today announced a series of leadership appointments to support the continued advancement and commercial planning of atuzaginstat, as well as the company’s pipeline expansion and regulatory affairs capabilities.
“Expanding Cortexyme’s leadership team strengthens our overall operations and brings additional depth and expertise to the company as we advance atuzaginstat’s development and related commercial planning, bolster our regulatory capabilities, and grow our clinical pipeline,” said Casey Lynch, Cortexyme